Relaxera is a pharmaceutical company focused on

• the development of a treatment of the aging heart (Heart Failure with preserved Ejection Fraction – HFpEF),

• protecting pancreatic cells against the glucotoxic effects caused by impaired glucose tolerance, and

• protecting organs in the field of transplantation medicine. 

Our pharmaceutical candidate is synthetic human relaxin-2, the “biological” is well known for its pleiotropic effects in the human body. Relaxera has developed methods for its synthesis in large quantities and is examining its effects on the heart muscle fibres, on the islet cells of pancreas, and selected organs for transplantation.

We have several cooperation projects with research institutes all over the world, e. g. the Heart and Vascular Institute of the University of Pittsburgh, the Division of Transplantation Surgery of the Medical University of Graz, or the Florey Institute of Neuroscience & Mental Health of the University of Melbourne.

We are open for further cooperation projects, contact us via med.science(at)relaxera.de or directly via our website.